Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 6/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25309664 | 0.89 | CHRNB2 (0.53) | CHRNB4CHRNA3CHRNB2CHRNA4ROCK2 | |
| SCHEMBL23744047 | 0.79 | PTPN11 (0.51) | CHRNB4CHRNA3 | |
| SCHEMBL24467741 | 0.79 | CHRNB4 (0.45) | CHRNB4CHRNA3CHRNB2CHRNA4ROCK2 | |
| SCHEMBL23744751 | 0.79 | PTPN11 (0.51) | CHRNB4CHRNA3 | |
| SCHEMBL29432181 | 0.77 | CHRNB4 (0.42) | CHRNB4CHRNA3CHRNB2CHRNA4ROCK2 | |
| SCHEMBL23744744 | 0.77 | CHRNB4 (0.49) | CHRNB4CHRNA3CHRNB2CHRNA4ROCK2 | |
| Hydrochloric Acid SCHEMBL26126547 | 0.75 | CHRNB4 (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4ROCK2 | |
| Hydrochloric Acid SCHEMBL25308897 | 0.75 | CHRNB4 (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4ROCK2 | |
| SCHEMBL20469047 | 0.72 | CHRNB2 (0.46) | CHRNB4CHRNA3CHRNB2CHRNA4ROCK2 | |
| SCHEMBL25147416 | 0.72 | MTOR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CHRNB4 1708/4885CHRNA3 1700/4885CHRNB2 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.